Corbus Pharmaceuticals Holding Total Liabilities
Corbus Pharmaceuticals Holding total liabilities. Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has total liabilities worth $24.75 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Corbus Pharmaceuticals Holding to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Corbus Pharmaceuticals Holding (2012–2025)
Total liabilities of Corbus Pharmaceuticals Holding from 2012 to 2025. This chart illustrates how Corbus Pharmaceuticals Holding's total liabilities have evolved over time, based on quarterly financial data.
Corbus Pharmaceuticals Holding Competitors by Total Liabilities
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Galway Metals Inc.
V:GWM
|
Canada | CA$2.40 Million |
|
Platform Turizm Tasimacilik AS
IS:PLTUR
|
Turkey | TL6.91 Billion |
|
R. Stahl AG NA O.N.
F:RSL2
|
Germany | €206.67 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM183.81 Million |
|
New Delhi Television Limited
NSE:NDTV
|
India | Rs7.78 Billion |
|
Moulinvest
PA:ALMOU
|
France | €64.85 Million |
|
Emkay Global Financial Services Limited
NSE:EMKAY
|
India | Rs15.74 Billion |
|
Spirit Technology Solutions Ltd
AU:ST1
|
Australia | AU$74.11 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Corbus Pharmaceuticals Holding's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Corbus Pharmaceuticals Holding (CRBP) total assets.
Liquidity & Leverage Metrics
Corbus Pharmaceuticals Holding Total Liabilities Ratios Explained
Corbus Pharmaceuticals Holding total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corbus Pharmaceuticals Holding's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corbus Pharmaceuticals Holding (2012–2025)
The table below shows the annual total liabilities of Corbus Pharmaceuticals Holding from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.69 Million | +53.83% |
| 2024-12-31 | $13.45 Million | -61.76% |
| 2023-12-31 | $35.18 Million | +5.57% |
| 2022-12-31 | $33.32 Million | -13.72% |
| 2021-12-31 | $38.62 Million | -32.27% |
| 2020-12-31 | $57.02 Million | +32.65% |
| 2019-12-31 | $42.98 Million | +120.83% |
| 2018-12-31 | $19.47 Million | +111.70% |
| 2017-12-31 | $9.19 Million | +2.52% |
| 2016-12-31 | $8.97 Million | +130.55% |
| 2015-12-31 | $3.89 Million | +427.11% |
| 2014-12-31 | $738.04K | -64.67% |
| 2013-12-31 | $2.09 Million | +280883.37% |
| 2012-12-31 | $743.36 | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more